Published in Proc Natl Acad Sci U S A on March 01, 2010
A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol (2013) 1.98
Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol (2010) 1.83
Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays. PLoS One (2013) 1.27
Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet (2014) 1.23
Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. Chem Biol (2012) 1.14
The essential roles of chemistry in high-throughput screening triage. Future Med Chem (2014) 1.12
Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet (2012) 1.11
Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med (2010) 1.10
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem (2015) 1.10
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA (2011) 1.08
Biochemical and structural characterization of bisubstrate inhibitors of BasE, the self-standing nonribosomal peptide synthetase adenylate-forming enzyme of acinetobactin synthesis. Biochemistry (2010) 1.04
Small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach. PLoS One (2011) 1.01
Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov (2012) 0.97
Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem (2011) 0.94
Bioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complex. Assay Drug Dev Technol (2012) 0.92
Doubts raised over 'read-through' Duchenne drug mechanism. Nat Biotechnol (2013) 0.91
Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy. Curr Pediatr Rep (2014) 0.89
Titration-based screening for evaluation of natural product extracts: identification of an aspulvinone family of luciferase inhibitors. Chem Biol (2011) 0.88
Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol (2012) 0.87
Zebrafish models flex their muscles to shed light on muscular dystrophies. Dis Model Mech (2012) 0.86
Innovation in academic chemical screening: filling the gaps in chemical biology. Curr Opin Chem Biol (2013) 0.85
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A (2016) 0.85
When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy. Medchemcomm (2014) 0.83
Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol Pharm (2014) 0.83
Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med (2013) 0.82
Differential scanning fluorometry signatures as indicators of enzyme inhibitor mode of action: case study of glutathione S-transferase. PLoS One (2012) 0.82
Structural and functional characterization of an anesthetic binding site in the second cysteine-rich domain of protein kinase Cδ*. Biophys J (2012) 0.81
Recent developments in the use of differential scanning fluorometry in protein and small molecule discovery and characterization. Expert Opin Drug Discov (2013) 0.80
Improved Synthesis of Biotinol-5'-AMP: Implications for Antibacterial Discovery. ACS Med Chem Lett (2014) 0.80
Non-nucleoside inhibitors of BasE, an adenylating enzyme in the siderophore biosynthetic pathway of the opportunistic pathogen Acinetobacter baumannii. J Med Chem (2013) 0.80
Real-time investigation of dynamic protein crystallization in living cells. Struct Dyn (2015) 0.79
Multi-modality imaging to determine the cellular heterogeneity of nasopharyngeal carcinoma components. Oncotarget (2014) 0.79
Novel small molecules potentiate premature termination codon readthrough by aminoglycosides. Nucleic Acids Res (2016) 0.78
Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review). Int J Mol Med (2014) 0.78
Recent advances using zebrafish animal models for muscle disease drug discovery. Expert Opin Drug Discov (2014) 0.77
The location and nature of general anesthetic binding sites on the active conformation of firefly luciferase; a time resolved photolabeling study. PLoS One (2012) 0.76
Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiae. PLoS One (2016) 0.75
High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics. Biology (Basel) (2014) 0.75
Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol (2016) 0.75
A novel aromatic carboxylic acid inactivates luciferase by acylation of an enzymatically active regulatory lysine residue. PLoS One (2013) 0.75
Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents. Appl Clin Genet (2011) 0.75
Toward postnatal reversal of ocular congenital malformations. J Clin Invest (2013) 0.75
Proposing a mechanism of action for ataluren. Proc Natl Acad Sci U S A (2016) 0.75
Small molecules as therapeutic agents for inborn errors of metabolism. J Inherit Metab Dis (2016) 0.75
Quantitative High-Throughput Screening Using a Coincidence Reporter Biocircuit. Curr Protoc Neurosci (2017) 0.75
Binding energy, specificity, and enzymic catalysis: the circe effect. Adv Enzymol Relat Areas Mol Biol (1975) 6.87
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Hydrogen bonding and biological specificity analysed by protein engineering. Nature (1985) 6.20
Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem (2006) 5.05
Errors and alternatives in reading the universal genetic code. Microbiol Rev (1989) 4.67
Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene (1991) 4.21
Structural basis for the spectral difference in luciferase bioluminescence. Nature (2006) 3.60
Crystal structure of firefly luciferase throws light on a superfamily of adenylate-forming enzymes. Structure (1996) 3.51
Recent developments in fragment-based drug discovery. J Med Chem (2008) 3.30
Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol (2007) 2.90
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem (2008) 2.53
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A (2009) 2.18
A specific mechanism for nonspecific activation in reporter-gene assays. ACS Chem Biol (2008) 2.08
The crystal structure of spermidine synthase with a multisubstrate adduct inhibitor. Nat Struct Biol (2002) 1.63
The synthesis and function of luciferyl-adenylate and oxyluciferyl-adenylate. J Biol Chem (1958) 1.47
Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A (2009) 1.09
Identification of ligand binding by protein stabilization: comparison of ATLAS with biophysical and enzymatic methods. Assay Drug Dev Technol (2008) 1.06
Coenzyme A affects firefly luciferase luminescence because it acts as a substrate and not as an allosteric effector. FEBS J (2005) 1.03
Synthesis of an N-acyl sulfamate analog of luciferyl-AMP: a stable and potent inhibitor of firefly luciferase. Bioorg Med Chem Lett (2005) 0.92
False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase. J Med Chem (2008) 0.91
Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase. Biochemistry (2001) 0.90
Mutation of a protease-sensitive region in firefly luciferase alters light emission properties. J Biol Chem (1997) 0.89
Rational design of enzyme inhibitors: multisubstrate analogue inhibitors. J Med Chem (1989) 0.89
A multisubstrate adduct inhibitor of a purine biosynthetic enzyme with a picomolar dissociation constant. J Med Chem (1989) 0.85
Comparison of formation of reactive conformers for the SN2 displacements by CH3CO2- in water and by Asp124-CO2- in a haloalkane dehalogenase. Proc Natl Acad Sci U S A (2003) 0.85
Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A (2006) 9.92
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
High-throughput screening assays for the identification of chemical probes. Nat Chem Biol (2007) 4.50
Hematotoxicity in workers exposed to low levels of benzene. Science (2004) 4.19
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (2011) 3.49
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science (2011) 3.30
Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect (2008) 3.11
A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem (2007) 2.97
Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med (2008) 2.90
Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One (2011) 2.61
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
Fluorescence spectroscopic profiling of compound libraries. J Med Chem (2008) 2.53
Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem (2008) 2.53
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin Cancer Res (2009) 2.48
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells. Cancer Epidemiol Biomarkers Prev (2010) 2.34
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A (2009) 2.18
Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer (2011) 2.12
Compound Management for Quantitative High-Throughput Screening. JALA Charlottesv Va (2008) 2.11
A specific mechanism for nonspecific activation in reporter-gene assays. ACS Chem Biol (2008) 2.08
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood (2006) 2.06
A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology (2008) 2.03
Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des (2003) 2.01
Segmental hair analysis after a single dose of zolpidem: comparison with a previous study. J Anal Toxicol (2013) 1.98
Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int (2010) 1.96
Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem (2009) 1.92
A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet (2011) 1.92
A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol (2008) 1.90
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol (2010) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem (2008) 1.81
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr Opin Chem Biol (2010) 1.76
Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods (2012) 1.75
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem (2010) 1.73
Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. J Med Chem (2006) 1.71
Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One (2010) 1.71
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.70
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet (2010) 1.69
Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 1.63
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem (2010) 1.61
Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci U S A (2009) 1.61
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem (2010) 1.60
Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis (2008) 1.58
Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis (2010) 1.56
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem (2010) 1.54
The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS). Acta Crystallogr D Biol Crystallogr (2008) 1.52
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
The Min oscillator uses MinD-dependent conformational changes in MinE to spatially regulate cytokinesis. Cell (2011) 1.49
Selective inhibition of 12-lipoxygenase protects islets and beta cells from inflammatory cytokine-mediated beta cell dysfunction. Diabetologia (2014) 1.49
A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics. Nucleic Acids Res (2009) 1.49
Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis (2004) 1.47
Variation in lung cancer risk by smoky coal subtype in Xuanwei, China. Int J Cancer (2008) 1.45
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem (2010) 1.45
Gustatory perception and behavior in Drosophila melanogaster. Curr Biol (2005) 1.41
Combined protein construct and synthetic gene engineering for heterologous protein expression and crystallization using Gene Composer. BMC Biotechnol (2009) 1.40
A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem (2006) 1.38
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett (2010) 1.37
Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. Chem Res Toxicol (2008) 1.37